James G. Zangrilli, MD
Philadelphia, PA 19107
(215) 955-0830 fax
Most Recent Peer-reviewed Publications
- Fixed airflow obstruction in asthma: A descriptive study of patient profiles and effect on treatment responses
- The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma
- Erratum: The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma (Drugs in R and D (2012) DOI: 10.2165/11630600- 000000000-00000)
- Systemic FasL neutralization increases eosinophilic inflammation in a mouse model of asthma
- Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: A randomized, controlled trial
Jefferson Medical College - 1988
Thomas Jefferson University Hospital 1989 - 1991
Thomas Jefferson University Hospital 1991 - 1995
Critical Care Medicine
Thomas Jefferson University Hospital
Assistant Professor of Medicine, 1996
Research & Clinical Interests
Dr. Zangrilli has been and remains active within the Division of Pulmonary and Critical Care at Thomas Jefferson University Hospital. He has a part-time appointment in the Pulmonary Critical Care Division where he sees outpatients, mentors fellows' clinic, and where he participates actively in several educational programs. His primary role is director, clinical research, respiratory and inflammation therapeutic area, AstraZeneca, Wilmington, Delaware.
Dr. Zangrilli graduated from Jefferson Medical College in 1988. He subsequently completed a 3-year residency training program at Thomas Jefferson University Hospital. This was followed by a 3-year fellowship in Pulmonary and Critical Care Medicine also at Thomas Jefferson University Hospital. In addition, he completed a year as a research fellow, followed by a year as a research associate also at Thomas Jefferson University. He has been an assistant professor since 1996 until his departure to industry in 2008. Dr. Zangrilli was the director of the Pulmonary/Critical Care Fellowship Program at Jefferson between 1999 and 2008, and he had successful re-accreditations for the ACGME Fellowship Program.
Dr. Zangrilli was productive on the tenure-track faculty while at Jefferson. He received several pilot awards including the Allen & Hansbury Pulmonary Fellowship in 1994 ($30,000 to study connective tissue regulation by immune cells from the asthmatic lung); Merck Young Investigators' Award in 1994; NIH Training Grant for program in Biomolecular Signal Transduction (program director was Gerald Litwack); received the American Lung Association Research Grant to study molecular mechanisms of eosinophil apoptosis ($25,000 a year). He was a co-investigator on several asthma related grants between 1986 and 2003. He was a principal investigator on an NIH K08 award from 1998 through 2004 for mechanisms of programmed cell death in eosinophils. He subsequently received an NIH RO1 between December 2004 and November 2009 where Dr. Zangrilli was a PI, for regulation of inflammation and asthma by Fas Ligand. Dr. Zangrilli lists 26 original peer-reviewed publications including 5 as a first author, including 3 publications in the past 12 months. In addition, he lists 10 book chapters and a variety of case reports and abstracts as well. Since transitioning to industry, Dr. Zangrilli has been the clinical lead on a phase II kinase inhibitor for asthma as well as several other emerging products for asthma.